SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 2

The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study

Gülay Güleç CEYLAN
Şükran ERTEN
İsmail DOĞAN
Ebru ATALAR
Kevser GÖK
Serdar Can GÜVEN
Yüksel MARAŞ
Pages
494–504
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Anti-interleukin-1 therapy could not fully suppress the subclinical inflammatory parameters when compared to healthy individuals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis.
📊
Key Findings & Data:Materials and methods: Forty-six FMF patients receiving anti-interleukin-1 therapy and 36 healthy control patients were compared in terms of laboratory parameters.
💡
Conclusion & Impact:Conclusion: Anti-interleukin-1 therapy could not fully suppress the subclinical inflammatory parameters when compared to healthy individuals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis. Materials and methods: Forty-six FMF patients receiving anti-interleukin-1 therapy and 36 healthy control patients were compared in terms of laboratory parameters. Also, FMF patients were further divided into two groups; those with amyloidosis and those without it, and these subgroups were compared to each other in terms of clinical and laboratory findings. Results: In comparison between the FMF and healthy control groups, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and red cell distribution width (RDW) level were detected to be higher and hemoglobin level lower in the patient group. Within the FMF patient group, the ESR, CRP, fibrinogen, RDW, and NLR values were significantly higher in the subgroup with amyloidosis in comparison to the subgroup without amyloidosis. Conclusion: Anti-interleukin-1 therapy could not fully suppress the subclinical inflammatory parameters when compared to healthy individuals.

🔖

Cite This Article

CEYLAN, G. G., ERTEN, Ş., DOĞAN, İ., ATALAR, E., GÖK, K., GÜVEN, S. C., MARAŞ, Y. (2022). The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 2, 494–504. https://ajindex.com/articles/609252

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43(2): 227–253. doi.org/10.1016/0002- 9343(67)90167-2
  2. Heller H, Sohar E, Pras M. Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathol Microbiol (Basel) 1961; 24: 718–723. doi.org/10.1159/000161188
  3. Kees S, Langevitz P, Zemer D, Padeh S, Pras M et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90 (10): 643–647. doi.org/10.1093/ qjmed/90.10.643
  4. Guzel S, Andican G, Seven A, Aslan M, Bolayirli M et al. Acute phase response and oxidative stress status in familial Mediterranean fever (FMF). Mod Rheumatol 2012; 22 (3): 431–437. doi.org/10.1007/s10165-011-0517-5
  5. Uslu AU, Deveci K, Korkmaz S, Aydin B, Senel S et al. Is neutrophil/lymphocyte ratio associated with subclinical inflammation and amyloidosis in patients with familial Mediterranean fever? Biomed Res Int 2013; 2013: 185317. doi. org/10.1155/2013/185317
  6. Yüksel S, Ayvazyan L, Gasparyan AY. Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J 2010; Feb 23 (4): 51–56. doi.org/10.2174/1874192401004020051
  7. Fonnesu C, Cerquaglia C, Giovinale M, Curigliano V, Verrecchia E et al. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009; 76 (3): 227–233. doi.org/10.1016/j.jbspin.2008.08.004
  8. Manna R, Cerquaglia C, Curigliano V, Fonnesu C, Giovinale M et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci 2009; 13 Suppl 1:51–53
  9. Ahsen A, Ulu MS, Yuksel S, Demir K, Uysal M et al. As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation 2013; 36 (6): 1357–1362. doi.org/10.1007/s10753-013-9675-2
  10. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 2009; 133 (4): 628–632. doi. org/10.1043/1543-2165-133.4.628
  11. Özer S, Yılmaz R, Sönmezgöz E, Karaaslan E, Taşkın S et al. Simple markers for subclinical inflammation in patients with Familial Mediterranean Fever. Med Sci Monit 2015; 21: 298– 303. doi.org/10.12659/MSM.892289
  12. Sakallı H, Kal O. Mean platelet volume as a potential predictor of proteinuria and amyloid